Citation Impact
Citing Papers
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
2019
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
2009 StandoutScience
Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer
2006
Autonomic Nerve Development Contributes to Prostate Cancer Progression
2013 StandoutScience
Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma
2006
Pharmacological inhibition of cystine–glutamate exchange induces endoplasmic reticulum stress and ferroptosis
2014 Standout
Comprehensive genomic characterization of head and neck squamous cell carcinomas
2015 StandoutNature
Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles
2006
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors
2008 Standout
6-Month Androgen Suppression Plus Radiation Therapy vs Radiation Therapy Alone for Patients With Clinically Localized Prostate Cancer
2004
Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence
2003
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
2006
Metabolic and cardiovascular effects of androgen deprivation therapy
2008
Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer
2001
Global Cancer Statistics, 2002
2005 Standout
Phase III Multi-Institutional Trial of Adjuvant Chemotherapy With Paclitaxel, Estramustine, and Oral Etoposide Combined With Long-Term Androgen Suppression Therapy and Radiotherapy Versus Long-Term Androgen Suppression Plus Radiotherapy Alone for High-Risk Prostate Cancer: Preliminary Toxicity Analysis of RTOG 99-02
2008
A Double-Blind, Placebo-Controlled, Randomized Trial of Oral Sodium Clodronate for Metastatic Prostate Cancer (MRC PR05 Trial)
2003
Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter
2004 Standout
Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy
1998
Administration of Cisplatin-Based Chemotherapy for Advanced Urothelial Carcinoma in the Community
2012
Imaging in the era of molecular oncology
2008 StandoutNature
Screening decreases prostate cancer death: First analysis of the 1988 Quebec Prospective Randomized Controlled Trial
1999
Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes
2002
Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications
2022 Standout
Noninvasive Detection of Clinically Occult Lymph-Node Metastases in Prostate Cancer
2003 Standout
Changes in Body Composition during Androgen Deprivation Therapy for Prostate Cancer
2002
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
2017
Leveling of prostate cancer mortality in Western Europe
2004
Biochemical Outcome Following External Beam Radiation Therapy With or Without Androgen Suppression Therapy for Clinically Localized Prostate Cancer
2000
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
2016 StandoutNobel
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
2007
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
2017 Standout
Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980–2007
2010
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 Standout
Global cancer statistics
2011 Standout
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
2006
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
2020 Standout
Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate Cancer
2008
Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53
2013
EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines
2013
EAU Guidelines on Prostate Cancer
2007 Standout
Bladder cancer
2016 Standout
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
2016 Standout
External beam radiation therapy for prostate cancer
2000
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
Androgen Deprivation Therapy for Localized Prostate Cancer and the Risk of Cardiovascular Mortality
2007
Cisplatin-Ineligible and Chemotherapy-Ineligible Patients Should Be the Focus of New Drug Development in Patients With Advanced Bladder Cancer
2013
Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions
2017
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Urothelial carcinoma management in elderly or unfit patients
2016
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
2007 Standout
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
2011 Standout
Increasing use of gonadotropin‐releasing hormone agonists for the treatment of localized prostate carcinoma
2005
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
2005 StandoutNature
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Annual report to the nation on the status of cancer, 1975–2004, featuring cancer in American Indians and Alaska Natives
2007
New Therapeutic Challenges in Advanced Bladder Cancer
2012
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
2015 Standout
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
2010 Standout
The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis
2019 StandoutNature
Mechanisms of Bone Metastasis
2004 Standout
Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate Cancer
1999
Trends in prostate cancer mortality among black men and white men in the United States
2003
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
The potential role of bisphosphonates in prostate cancer
2002
Tumor Angiogenesis
2008 Standout
Cancer Statistics, 2010
2010 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Gonadotropin-Releasing Hormone Agonists and Fracture Risk: A Claims-Based Cohort Study of Men With Nonmetastatic Prostate Cancer
2005
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Over One Hundred Peptide-Activated G Protein-Coupled Receptors Recognize Ligands with Turn Structure
2005
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Self-Assembled Monolayers of Thiolates on Metals as a Form of Nanotechnology
2005 Standout
Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis
2016 Standout
Imaging of Prostate-Specific Membrane Antigen with Small-Molecule PET Radiotracers: From the Bench to Advanced Clinical Applications
2019
A Phase II Clinical Trial of Neoadjuvant Ketoconazole and Docetaxel Chemotherapy Before Radical Prostatectomy in High Risk Patients
2011
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Comprehensive Comparison of Health-Related Quality of Life After Contemporary Therapies for Localized Prostate Cancer
2002
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 Standout
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
2006 Standout
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
2002 Standout
Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
2011
Chemistry and Biology Of Multicomponent Reactions
2012 Standout
Exceedingly small iron oxide nanoparticles as positive MRI contrast agents
2017 StandoutNobel
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer
2006
Works of Thierry Gil being referenced
Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986
2011
A phase I study of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced, solid tumors
2004
Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers
2004
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
2005
Paget bone disease demonstrated on 68Ga-PSMA ligand PET/CT
2015
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
2011
Phase II study of vinorelbine in patients with androgen-independent prostate cancer
2001
Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin
1997
Clinical impact of 68 Ga‐prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate‐specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach
2016
Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin-based chemotherapy (CHT): Phase III results of EORTC study 30986.
2010
381 A phase I study of BAY 43-90006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced solid tumors
2004
Checkpoint Inhibitors in Bladder and Renal Cancers: Results and Perspectives
2015